For the study, researchers accessed the Blue Cross Blue Shield of Texas claims database to track annual drug costs — along with hypertension-related outpatient and inpatient healthcare costs — for 6,000 patients who had their blood pressure medication modified within one year of starting the regimen between 2008 and 2012.
Patients who switched to a fixed-dose combination therapy represented the most expensive treatment option upfront, costing the an average of $310 per patient, followed by switching to a new drug ($135), gradually increasing the dose of the current medication ($63) and gradually decreasing the current drug’s dose ($61).
When researchers accounted for follow-up healthcare costs, patients taking a fixed-dose combination therapy cost the health plan the least at an average of $1,731. Patients who decreased the dose of their current drug cost the insurer an average of $2,985. Individuals who switched to a new drug or increased the dose of the current drug cost the health plan $7,076 and $7,692, respectively.
“Even though the drug costs for fixed-dose combination appear to be extremely high, it is offset by savings in health services costs, saving almost seven times the cost in inpatient visits,” lead author Kalyani Sonawane, PhD, told Science Daily.
More articles on supply chain:
Viewpoint: Supply chain needs more diversity
Mallinckrodt considers sale of generic drug unit: 4 things to know
Medicare patients don’t see benefits of drug rebates, says researchers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.